Attached files
| file | filename |
|---|---|
| EX-10.14 - EX-10.14 - Magenta Therapeutics, Inc. | d549494dex1014.htm |
| EX-10.2 - EX-10.2 - Magenta Therapeutics, Inc. | d549494dex102.htm |
| EX-5.1 - EX-5.1 - Magenta Therapeutics, Inc. | d549494dex51.htm |
| EX-4.1 - EX-4.1 - Magenta Therapeutics, Inc. | d549494dex41.htm |
| EX-3.4 - EX-3.4 - Magenta Therapeutics, Inc. | d549494dex34.htm |
| EX-3.2 - EX-3.2 - Magenta Therapeutics, Inc. | d549494dex32.htm |
| S-1/A - S-1/A - Magenta Therapeutics, Inc. | d549494ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Magenta Therapeutics, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Cambridge, Massachusetts
June 7, 2018